The story addressed most of our criteria, but we felt it could have been improved a bit by even brief mention of the cost impact of implementing such a system, and a little more context on the Archimedes system and related research.
Overall, though, good job.
Finding more cost effective and more efficient means of treating people with high blood pressure has great potential for health policy – as does the broader approach of using risk calculators in electronic medical records.
Couldn’t Dr. Eddy have commented on the projected cost of implementing his idea? And certainly the projected cost saving impact of his Archimedes system has been the focus of past news coverage. So even a line about cost impact would have been appreciated.
Mixed bag here, but we’ll give the story the benefit of the doubt.
The benefits from the use of models to better fit treatment recommendations were described as relative improvements rather than absolute benefits. That’s how the data were described in the abstract of the paper reported on; the predicted numbers were contained within the body of the article. Given the size of the population in question, we can look the other way on the use of relative risk reduction figures.
And, as already noted, the story injected some caution about real world benefits by quoting an independent expert:
We don’t know what the harms would be of the idealized “tailored medicine” approach described in the piece.
The story did an adequate job explaining how the analysis was done. And, through the words of an independent expert (author of an editorial accompanying the journal article), it injected some real-world cautions:
The story did not engage in disease mongering.
The comments from the author of the editorial that accompanied the journal article were helpful.
The entire focus of the story was a comparison of a “tailored medicine” approach to existing guidelines for treatment of high blood pressure.
It would have been interesting to explore whether this is the only model for tailoring clinical information to arrive at better clinical outcomes or whether there are other models available for this purpose.
The story could have been more explicit about the availability – or lack thereof – of the computerized risk calculator in question.
However, a reader should be able to deduce from the following hints that the idea is not in widespread use:
The story could have done a better job providing even a brief background on the Archimedes system and past reports about this or related research. A reader might think this was the very first news about this approach.
It’s clear that the story did not rely solely on a news release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like